ARS Investment Partners LLC purchased a new stake in shares of Celgene Corporation (NASDAQ:CELG) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,783 shares of the biopharmaceutical company’s stock, valued at approximately $222,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Motco boosted its position in Celgene Corporation by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 620 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. bought a new position in Celgene Corporation during the first quarter valued at about $118,000. Oakworth Capital Inc. boosted its position in Celgene Corporation by 60.9% in the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 412 shares in the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its position in Celgene Corporation by 47.5% in the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 380 shares in the last quarter. Finally, Reilly Financial Advisors LLC boosted its position in Celgene Corporation by 15.3% in the first quarter. Reilly Financial Advisors LLC now owns 1,211 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 161 shares in the last quarter. 79.43% of the stock is currently owned by institutional investors.

Celgene Corporation (NASDAQ CELG) traded up 1.582% on Wednesday, reaching $134.535. 856,713 shares of the company’s stock were exchanged. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $139.00. The firm has a market cap of $105.25 billion, a PE ratio of 41.665 and a beta of 1.89. The firm’s 50-day moving average is $133.39 and its 200-day moving average is $125.39.

Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. During the same quarter in the prior year, the business posted $1.44 EPS. The business’s revenue was up 18.7% compared to the same quarter last year. On average, equities analysts forecast that Celgene Corporation will post $7.32 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “1,783 Shares in Celgene Corporation (CELG) Acquired by ARS Investment Partners LLC” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.watchlistnews.com/1783-shares-in-celgene-corporation-celg-acquired-by-ars-investment-partners-llc/1532160.html.

Several research firms have issued reports on CELG. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $175.00 price target (up previously from $148.00) on shares of Celgene Corporation in a report on Monday, July 31st. Cantor Fitzgerald set a $160.00 price target on Celgene Corporation and gave the company a “buy” rating in a report on Thursday, July 27th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $160.00 price target (up previously from $152.00) on shares of Celgene Corporation in a report on Friday, July 28th. Canaccord Genuity set a $156.00 price target on Celgene Corporation and gave the company a “buy” rating in a report on Tuesday, June 6th. Finally, BidaskClub raised Celgene Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. One analyst has rated the stock with a sell rating, six have given a hold rating and twenty-three have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $147.38.

In related news, Director Gilla Kaplan sold 7,500 shares of the stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total transaction of $1,008,900.00. Following the completion of the transaction, the director now owns 76,301 shares in the company, valued at $10,264,010.52. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Ernest Mario sold 18,506 shares of the stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the transaction, the director now owns 69,424 shares of the company’s stock, valued at approximately $9,061,220.48. The disclosure for this sale can be found here. In the last quarter, insiders sold 253,761 shares of company stock valued at $33,792,445. Company insiders own 0.95% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.